Triana Raises $110M to Solve Undruggable Cancer Targets with Molecular Glue

Triana Biomedicines leaped out of stealth mode with $110 million in Series A financing that will be used to fund its mission to discover and develop novel small molecules to treat diseases. These molecules then become the backbone of a scalable “molecular glue.”